Washington Examiner
Sign in Subscribe
News
Politics
White House
Senate
House
Campaigns
Business
World
Investigations
Justice
Supreme Court
Crime
Entertainment
Washington Secrets
Policy
Defense
National Security
Energy and Environment
Education
Immigration
Finance and Economy
Healthcare
Foreign Policy
Tech
Infrastructure
Space
2026 Election
America at 250
IN FOCUS
Commentary
Columnists
Editorials
Think Tanks
Beltway Confidential
Op-Eds
Restoring America
Patriotism and Unity
Faith, Freedom, and Self-Reliance
Courage, Strength, and Optimism
Equality, Not Elitism
Community and Family
Fairness and Justice
Mission
Watch
Magazine
Magazine
Quarterly Briefing
Archives
Games
Sponsored
Protecting Air Ambulance Services
Powering Progress
ASAE – Association Leadership
National Parks
Examining Tax Reform
Fix TSCA
Inside the Corn Belt
Examining Transportation
Newsletters
Sign In Sign InHome
News
Politics
Policy2026 Election
Opinion
EditorialsOp-Eds
In FocusRestoring AmericaMagazineWatch
Sponsored
Protecting Air Ambulance ServicesPowering ProgressASAE – Association LeadershipNational ParksExamining Tax ReformFix TSCAInside the Corn BeltExamining Transportation
TWS Archive
Advertisement
Home › Authors › Posts by Matthew Perrone

Matthew Perrone

Read the latest stories and analysis from Matthew Perrone.

Business

FDA weighs over-the-counter approval of Singulair

Matthew Perrone · April 30, 2014 2:44 pm
Business

FDA wants stricter safety rules for pelvic mesh

Matthew Perrone · April 29, 2014 10:11 pm
Business

FDA reviews psychiatric side effects of Chantix

Matthew Perrone · April 25, 2014 9:35 pm
Business

FDA OKs first-ever DNA alternative to Pap smear

Matthew Perrone · April 24, 2014 10:06 pm
Business

FDA warns of cancer risk with fibroid procedure

Matthew Perrone · April 17, 2014 9:28 pm
Business

DNA alternative to Pap smear sparks medical debate

Matthew Perrone · April 15, 2014 7:23 pm
Business

Under fire, Zohydro maker touts drug safety board

Matthew Perrone · March 26, 2014 1:29 pm
Business

Marijuana study in veterans wins federal backing

Matthew Perrone · March 17, 2014 2:03 pm
Business

FDA chief defends Zohydro as criticism intensifies

Matthew Perrone · March 13, 2014 6:30 pm
Business

OxyContin maker to offer abuse-resistant Zohydro

Matthew Perrone · March 12, 2014 4:13 pm
Business

Medical groups question price of new hep C drug

Matthew Perrone · March 11, 2014 6:17 pm
Business

Endo gets US approval for long-acting testosterone

Matthew Perrone · March 6, 2014 5:14 pm
Advertisement
  • ‹Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 13
  • ›Next page
Page 4 of 13
Advertisement
Washington Examiner Manage Preferences

News

  • Politics
    • White House
    • Senate
    • House
    • Campaigns
  • Business
  • World
  • Investigations
  • Justice
  • Supreme Court
  • Crime
  • Washington Secrets
  • Entertainment
  • Sports

Policy

  • Defense
  • National Security
  • Energy
  • Immigration
  • Finance and Economy
  • Healthcare
  • Foreign Policy
  • Tech
  • Infrastructure
  • Space

Commentary

  • Columnists
  • Editorials
  • Think Tanks
  • Beltway Confidential
  • Op-Eds

Restoring America

  • Patriotism & Unity
  • Faith, Freedom & Self-Reliance
  • Courage, Strength & Optimism
  • Equality, Not Elitism
  • Community & Family
  • Fairness & Justice
  • Mission

Watch

  • Shows
NEWSLETTERS MAGAZINE ARCHIVE
  • Policies and Standards
  • Terms Of Service
  • Subscription Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Transparency In Coverage
  • Advertise
  • Subscribe
  • Contact
  • Careers
  • Staff
  • About Examiner
  • Facebook
  • Twitter
© Copyright 2026. Washington Examiner. All Rights Reserved.
Advertisement